ReviewBJPsych open2023
A systematic review of the print media representation of ketamine treatments for psychiatric disorders.
Review in BJPsych open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 9 citations in OpenAlex.
- Ketamine Use in Self-Described Therapeutic Contexts: A Thematic Analysis of Reddit Posts.Behavioral sciences (Basel, Switzerland) · 2026Article
- Patient-centred education for ketamine and esketamine therapies in mood disorders.Therapeutic advances in psychopharmacology · 2026Review
- Trends in ketamine use among nightclub attendees in New York City, 2017-2024.The International journal on drug policy · 2025Article
- Ketamine Versus Electroconvulsive Therapy for the Treatment of Depression: A Guide for Clinicians.Focus (American Psychiatric Publishing) · 2025Article
- Trends and characteristics in ketamine use among US adults with and without depression, 2015-2022.Journal of affective disorders · 2025Article
- An easily fabricated nanoporous Au membrane in drug detection with reusable functionality and high SERS performance.Mikrochimica acta · 2024Article
- Implementation of a ketamine programme for treatment-resistant depression in the public health system: Lessons from the first Australian public hospital clinic.The Australian and New Zealand journal of psychiatry · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundPublic and patient expectations of treatment influence health behaviours and decision-making.
aimsWe aimed to understand how the media has portrayed the therapeutic use of ketamine in psychiatry.
methodWe systematically searched electronic databases for print and online news articles about ketamine for psychiatric disorders. The top ten UK, USA, Canadian and Australian newspapers by circulation and any trade and consumer magazines indexed in the databases were searched from 2015 to 2020. Article content was quantitatively coded with a framework encompassing treatment indication, descriptions of prior use, references to research, benefits and harms, treatment access and process, patient and professional testimony, tone and factual basis.
resultsWe found 119 articles, peaking in March 2019 when the United States Food and Drug Administration approved esketamine. Ketamine treatment was portrayed in an extremely positive light (
conclusionsInformation pertinent to patient help-seeking and treatment expectations is being communicated through the media and supported by key opinion leaders, although some quotes go well beyond the evidence base. Clinicians should be aware of this and may need to address their patients' beliefs directly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.